Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Famy Life Sciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.

            Lead Product(s): Undisclosed

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $280.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition January 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.

            Lead Product(s): Undisclosed

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY